|  |  |  |
| --- | --- | --- |
| **Program:**  | **Client:** | **Gender:** |
| **Psychiatrist:** | **Case#:** | **Date of last MD visit:** |
| **Review Date:** | **DOB:** | **Age:** | **Wt (lb):** | **Ht (in):** |
| **Reviewer:** | **Allergies:****[ ]  NKDA** **[ ]  Other:** |
|  **Reviewer:** | **Diagnosis:** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **CRITERIA** | **YES** | **NO** | **N/A** | **COMMENTS** |
| **1** | Medication dose(s) within the usual recommended dose(s) as defined in California Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care, [Guidelines](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_B.pdf) [Appendix B](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_B.pdf) - (Los Angeles County Department of Mental Health’s Parameters 3.8 for Use of Psychotropic Medications for Children and Adolescents) | [ ]  | [ ]  | [ ]  |  |
| **2** | Were labs indicated?1. For youth newly prescribed antipsychotic medication, were labs for fasting blood glucose or HbA1C and LDL- C/cholesterol obtained 90 days prior to initial prescribing or within 15 days thereafter?
2. For youth on antipsychotic medication for > 30 days, were monitoring labs for fasting blood glucose or HbA1C and LDL-C/cholesterol obtained 90 within the past 12 months (to be obtained annually)?
3. Were labs indicated for classes of medication other than antipsychotic medication?
4. Were all indicated labs obtained (For antipsychotic medication and for other classes)?
5. Were the labs reviewed by Medical Staff?
6. Were the lab results present in the chart?
7. Were attempts made to obtain appropriate baseline labs within 90 days prior to prescribing or 15 days thereafter?
8. If treatment continues without labs, is there appropriate rationale to continue/discontinue medications?
9. Evidence of documented clinical justification and/or treatment plan adjustment when requested labs have not been completed for any reason?
 | [ ] a[ ] b[ ] c[ ] d[ ] e[ ] f[ ] g[ ] h[ ] i[ ]  | [ ] a[ ] b[ ] c[ ] d[ ] e[ ] f[ ] g[ ] h[ ] i[ ]  | a[ ] b[ ] c[ ] d[ ] e[ ] f[ ] g[ ] h[ ] i[ ]  | **If labs are *not* indicated - mark NO, 2a - 2h should be marked N/A; this would *not* be a variance, no McFloops required. \*McFloop not required when missing labs are due to client noncompliance.****\*If 2i is marked No, a McFloop is required with explanation.** |
| **3** | Physical health conditions and treatment are considered when prescribing psychiatric medication. | [ ]  | [ ]  | [ ]  |  |
| **4** | If the youth was prescribed a new psychotropic medication, was there a follow-up visit with a practitioner with prescribing authority within 30 days? | [ ]  | [ ]  | [ ]  | **\*McFloop is required if follow up appt is not completed within 30 days unless it was due to client no-show or refusal.**  |
| **5** | Is the patient on more than one medication of any of the following chemical classes concurrently? | [ ]  | [ ]  | [ ]  |  |
|  | a. **Stimulants:** (This does not include a long-activating stimulant and immediate-release stimulant that is the same chemical entity, e.g.; Methylphenidate-OROS and Methylphenidate)a1. If “yes,” is rationale documented?a2. If the stimulant was newly prescribed, was the CURES database checked before prescribing, and was that documented?a3. If the stimulant prescription is ongoing, has the CURES database been checked at least every 6 months and is that documented? | [ ] [ ] [ ] [ ]  | [ ] [ ] [ ] [ ]  | [ ] [ ] [ ]  | **If stimulants *not* prescribed – then mark NO, a1-a3 should be marked N/A; this would not be a variance, no McFloops required** |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **CRITERIA** | **YES** | **NO** | **N/A** | **COMMENTS** |
| b. **Mood Stabilizers:**(Antipsychotics not included)If “yes”, is rationale documented? | [ ] [ ]  | [ ] [ ]  | [ ] [ ]  |  |
| c. **Antidepressants:**(Trazodone as hypnotic excepted)If “yes”, is rationale documented? | [ ] [ ]  | [ ] [ ]  | [ ] [ ]  |  |
| d. **Antipsychotics:****(**Any combination of atypical and typical)If “yes”, is rationale documented? | [ ] [ ]  | [ ] [ ]  | [ ] [ ]  |  |
| **e. Anticholinergic agents:**If “yes”, is rationale documented? | [ ] [ ]  | [ ] [ ]  | [ ] [ ]  |  |
| **f. Hypnotics:**Including trazodone, diphenhydramine, zolpidem, melatonin, benzodiazepines. Not including clonidine, guanfacine & prazosin.f1. If “yes”, is rationale documentedf2. If the hypnotic was a Schedule IV medication (benzodiazepine, zolpidem, eszopiclone, zaleplon) and was newly prescribed, was the CURES database checked before prescribing, and was that documented?f3. If the Schedule IV hypnotic prescription is ongoing, has the CURES database been checked at least every 6 months and is that documented? | [ ] [ ] [ ] [ ]  | [ ] [ ] [ ] [ ]  | [ ] [ ] [ ] [ ]  | **If hypnotics *not* prescribed – then mark NO, f1-f3 should be marked N/A; this would not be a variance, no McFloops required** |
| **6** | Adverse drug reactions and/or side effects treated and managed effectively | [ ]  | [ ]  | [ ]  |  |
| **7** | Informed consent is evidenced by a signed consent form. | [ ]  | [ ]  | [ ]  |  |
| **8** | Documentation is in accordance with prescribed medication. | [ ]  | [ ]  | [ ]  |  |
| **9** | **Documentation includes client’s:** |  |
|  | a. Response to medication therapy? | [ ]  | [ ]  | [ ]  |  |
| b. Presence/absence of side effects? | [ ]  | [ ]  | [ ]  |  |
| c. Extent of client’s adherence with the prescribed medication regimen and relevant interventions? | [ ]  | [ ]  | [ ]  |  |

There are continued active legislative changes around the use/monitoring of psychotropic medications with youth. The County of San Diego will continue to disseminate information about legislative changes to the Children’s System of Care.

The Department of Social Services (CDSS), in collaboration with stakeholders, developed measures to track youth in foster care who received a paid claim for psychotropic medication from the California Department of Health Care Services. These measures will be publicly posted with the goal of improving the health and well-being of youth in care. Select measures have been added to this tool. Please see link provided for complete list.

[QIP Foster Care](https://www.dhcs.ca.gov/provgovpart/pharmacy/Pages/qip-foster-care.aspx)

Senate Bill 482 was passed in 2016 and now requires that the CURES database be reviewed before Schedule II, III or IV controlled substances are prescribed for the first time and at least once every four months thereafter if the prescribed controlled substance remains part of the patient’s treatment. As of July 1, 2021 the requirement to review the CURES database if a controlled substance remains a part of treatment has been amended to every six (6) months.

In April 2015, Department of Health Care Services published “California Guidelines for the Use of Psychotropic

Medication with Children and Youth in Foster Care” These guidelines target youth involved in county child welfare and probation agencies and is specific to those children and youth who are placed in foster care. Foster Care is defined as 24 hour substitute care for children placed away from their parents or guardians and for whom the State and/or county agency has placement care responsibility. This includes, but is not limited to, placements in foster family homes, foster homes of relatives, group homes, emergency shelters, residential facilities, child care institutions, and pre-adoptive homes**.**

# For detailed information on the California Guidelines: (links provided)

[CA Guidelines for the Use of Psychotropic Medication with Children and Youth in Foster Care](http://www.dhcs.ca.gov/provgovpart/pharmacy/Pages/QIPFCP/Clinical.aspx) [Guidelines Appendix A](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_A.pdf) - Prescribing Standards of Psychotropic Medication Use by Age Group [Guidelines Appendix B](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_B.pdf) - Parameters for Use of Psychotropic Medication for Children and Adolescents [Guidelines Appendix C](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_C.pdf) - Challenges in Diagnosis and Prescribing of Psychotropic Medications [Guidelines Appendix D](http://www.dhcs.ca.gov/provgovpart/pharmacy/Documents/QIP_Appendix_D.pdf) - Algorithm (Decision Tree) for Prescribing Psychotropic Medications

Please review the medical record **AS IF** the CA Guidelines applied for question number 10.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **CRITERIA** | **YES** | **NO** | **N/A** | **COMMENTS** |
| **10** | **Is the patient on more than the allowable medications for their age group per prescribing standards detailed in the CA Guidelines?** |  |
|  | 1. **Age 12 – 17 - Less than 4 psychotropic medications (allows no more than 3)**
	1. Does the number of medications prescribed meet the standards?
 | [ ]  | [ ]  | [ ]  |  |
|  | 1. **Age 6 – 11 – Less than 3 psychotropic medications (allows no more than 2)**
	1. Does the number of medications prescribed meet the standards?
 | [ ]  | [ ]  | [ ]  |  |
|  | 1. **Age 0 – 5 - Less than 2 psychotropic medications (allows 1)**
	1. CA Guidelines allows for stimulant, atomoxetine, guanfacine, clonidine or risperidone (risperidone for autistic spectrum disorders and associated aggression only). Does the prescribing meet the Guideline recommendation?
	2. Does the number of medications prescribed meet the standards?
 | [ ] [ ]  | [ ] [ ]  | [ ] [ ]  |  |

**Please complete a McFloop Form if there are any variances and submit to County QM along with this tool and**

**Submission Form. Forms can be sent via confidential fax to 619-236-1953 or encrypted email at: Qimatters.hhsa@sdcounty.ca.gov.**